RDIF and Morepen Laboratories announce test batch manufacturing of Sputnik V in India

The Russian Direct Investment Fund (RDIF) and Morepen Laboratories announced the production of the test batch of the Russian Sputnik V coronavirus vaccine in an exclusive facility in the state of Himachal Pradesh (HP).

The first batch will be shipped to the Gamaleya Center for quality control. RDIF and Morepen Laboratories signed a cooperation agreement in June 2021 and are actively implementing the technology transfer.

Sputnik V was granted an emergency use authorization in India on April 12, 2021. RDIF had reached agreements earlier with other pharma companies in India – Gland Pharma, Hetero Biopharma, Panacea Biotec, Stelis Biopharma and Virchow Biotech. In total, agreements with partners in India provide for production of more than 850 mn doses of Sputnik V per year.

Kirill Dmitriev, CEO of the Russian Direct Investment Fund, commented, “As the pandemic is yet far from over and new, more dangerous variants of coronavirus are being detected in various regions of the world, RDIF is increasing capacities for production of Sputnik V in India, one of the key hubs. Agreement with Morepen Laboratories provides for a larger amount of Sputnik V to be available both for India and our partners globally to speed up the vaccination with one of the best vaccines in the world.”

Sushil Suri, Chairman & MD of Morepen Laboratories commented, “We are delighted to partner with RDIF for the prestigious project of Sputnik V production in India. This would be our privilege to work jointly on expanding the production base in India. We take this partnership as a starting point for a long term relationship with RDIF and its partner companies as we look forward to many more areas of common interest. Morepen’s commitment towards this project is a step forward towards entry into biosimilars and other biologicals.”